Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TUDCA in mild asthma
NCT03878654Phase 1Terminated
- Sponsor
- The University of Vermont
- Start
- Jan 2019
- Primary completion
- Sep 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of tauroursodeoxycholic acid in asthma, sponsored by The University of Vermont. Primary endpoints: Aspartate Aminotransferase at 12 weeks, Alanine Aminotransferase at 12 weeks and 10 more. Started Jan 2019; status: terminated.
02
Drugs
tauroursodeoxycholic acid
03
Conditions
asthma
Beyond the preview
Go deeper on NCT03878654.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03878654.